September 24th, Switzerland

Free Registration, Part of MipTec 2014, Congress Center Basel

Scientific Program

The program is subject to change. Please check this section periodically.


LATEST UPDATE: 09.19.2014
please update your schedules

Meeting Location:
Congress Center Basel, MipTec Conference, Scientific Forums

Room 2
Day 1: Tuesday, September 23, 2014, Room 2
08:45-09:00
Introduction to Forum and Day 1

Forum chairs: Alex Zhavoronkov, PhD, Bhupinder Bhullar, PhD
Keynotes and Hallmarks of Aging Research
09:00 - 09:20
Advances in aging biomarkers and drugs with geroprotective properties

Brian Kennedy PhD, Director, CEO, Buck Institute for Aging Research
09:20 - 09:40
New approaches in aging diagnostics

Charles Cantor PhD, Professor, Boston University
09:40 - 10:00
The example of the discovery and development of of mitochondrial derived peptides to delay aging

Nir Barzilai, Director, Albert Einstein College of Medicine
10:00-10.20
Effects of mTOR Inhibition on Immunosenescence  in Elderly Humans

Joan Mannick, MD, Director, Translational Medicine, Novartis Institute for Biomedical Research
10:20-10:40
Break
Session I: Predicting the activity of geroprotective drugs: in-silico screening, omics data analysis and rational drug design
Session Chair: Joao Pedro Megalhaes, PhD
10:40 - 11:00
Novel methods for selecting targeted drugs for personalized medicine in oncology

Anton Buzdin, PhD, DSc, President, CEO, Pathway Pharmaceuticals, Hong Kong
11:00 - 11:20
Bioinformatic analysis of the “omics” data from long-lived animals for geroprotector discovery

Joao Pedro De Magalhaes, PhD, Lab Head, University of Liverpool
11:20 - 11:40
In silico screening for novel drugs with geroprotective properties

Alexander Zhavoronkov, PhD, Director, The Biogerontology Research Foundation, CEO, Insilico Medicine, Inc
11:40 - 12:00
Using novel isotopically-fortified organic compounds to slow down aging processes and treat aging-related diseases

Charles Cator, PhD (on behalf of Robert Molinari, PhD, CEO, Retrotope, Inc)
12:00 -13:30
Lunch and Industry symposia
Room 5
Keynote address: R&D productivity: revival or further decline?
13:30 - 14:15
Dr. Joerg Reinhardt, Chairman of the Board of Directors, Novartis


Session II: Drugs with the potential geroprotective properties
Session Chair: Alexey Moskalev, PhD, DSc
14:30-14:40
Introduction to Session II

Bhupinder Bhullar, PhD
14:40 - 15:00
Advances in the Advanced Glycation Endproduct (AGE) breakers

William Bains, PhD, Head of the SENS Laboratory, Cambridge
15:00 - 15:20
Overview of the possible geroprotectors

Sven Bulterijs, PhD, Post-grad researcher, Yale University
15:20 - 15:40
Applied Epigenetics of Aging and Longevity

Olga Kovalchuk, PhD, Professor, Lab Head, University of Lethbridge, Director, Canada Cancer and Aging Research Laboratories
15:40-16:00
Break
16:00 - 17:00
Roundtable Discussion: How can Pharma engage in aging research?

Moderator: Alex Zhavoronkov, PhD


Day 2: Wednesday, September 24, 2014
08:45 - 09:00
Introduction to Forum and Day 2

Forum Chairs: Alex Zhavoronkov, PhD, Bhupinder Bhullar, PhD
Keynotes and Hallmarks of Aging Research
09:00 - 09:20
Rapamycin and other geroprotectors

Mikhail Blagosklonny, MD, PhD, Professor, Editor-in-Chief of Aging, Cell Cylcle and Oncotarget high-impact journals, Rosewell Park, NY
09:20 - 09:40
The role of Indy in fly health and longevity

Blanka Rogina, PhD, Director Genetics & Developmental Biology Graduate Program, University of Connecticut
09:40 - 10:00
Translating Advances from the Basic Biology of Aging into Clinical Application: Opportunities and Challenges

James Kirkland, MD, PhD, Professor, Mayo Clinic
10:00 - 10:20
How to Solve Genetic Disease on a Population Scale

Barry Merriman, PhD, Professor, UCLA / Lead System Architect, CSO, Thermo Fisher Scientific
10:20 - 10:40
Coffee Break
Session III: Aging Biomarkers: how do we measure aging and geroprotective efficacy
Session Chair: Alexander Bürkle, PhD
10:40 - 11:00
Lessons learned from the EU FP7 MARKAGE Project

Alexander Bürkle, PhD, Professor, EU MARK-AGE Co-ordinator, University of Konstanz
11:00 - 11:20
Comparative genomics of aging and longevity

Vadim Gladyshev, PhD, Professor, Department of Medicine, Harvard Medical School, Director of Redox Medicine, Medicine, Brigham And Women's Hospital, Harvard
11:20 - 11:40
Gene expression patterns in progeria, age-related macular degeneration (AMD) and other age-related diseases

Antonei Benjamin Csoka, PhD, Assoc. Professor, Howard University, CEO, Vision Genomics, Inc
11:40 - 12:00
Experimental approaches to screening of aging-suppressive drugs

Alexey Moskalev, PhD, DSc, Professor, head of the laboratory Moscow Institute of Physics and Technology
12:00 - 13:30
Lunch and Industry Symposia
Room 5
Keynote Address: TBD
13:30 - 14:15
 Dr. Patrick Aebischer,  President Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland
Session IV: Trends in Aging Research for Drug Discovery
Session Chair: Richard Faragher, PhD
14.30 - 15:00
Pharmacological prospects for health span extension

Richard Faragher, Professor, University of Brighton
15:00-15:30
Ageing Research and Regenerative Medicine Industry Outlook

Geoffrey Furlonger, CEO, Aging Analytics, Charles Groome, Head of Communications, Aging Analytics UK
15:30 - 16:00
Big Data in Biomedicine: Applying machine learning to predict the outcomes of biomedical research projects

Dmitry Kaminskiy, Director, Senior Partner, Deep Knowledge Ventures
16:00 - 16:20
Coffee Break
16:20 - 16:40
Trends in aging research policy: past, present and future

Dan Perry, CEO, Alliance for Aging Research, USA
16:40-17:00
Concluding remarks and follow up publications

Bhupinder Bhullar, PhD, Director, Novartis; Alex Zhavoronkov, PhD, CEO, Insilico Medicine, Inc






LATEST UPDATE: 09.13.2014

Meeting Location:
Congress Center Basel, MipTec Conference, Scientific Forums

Room 2
Day 1: Tuesday, September 23, 2014, Room 2
08:45-09:00
Introduction to Forum and Day 1

Forum chairs: Alex Zhavoronkov, PhD, Bhupinder Bhullar, PhD
Keynotes and Hallmarks of Aging Research
09:00 - 09:20
Advances in aging biomarkers and drugs with geroprotective properties

Brian Kennedy PhD, Director, CEO, Buck Institute for Aging Research
09:20 - 09:40
New approaches in aging diagnostics and interventions

Charles Cantor PhD, Professor, Boston University
09:40 - 10:00
TBD

Nir Barzilai, Director, Albert Einstein College of Medicine
10:00-10.20
Effects of mTOR Inhibition
on Immunosenescence  in Elderly Humans

Joan Mannick, PhD, Director, Translational Medicine, Novartis Institute for Biomedical Research
10:20-10:40
Break
Session I: Predicting the activity of geroprotective drugs: in-silico screening, omics data analysis and rational drug design
Session Chair: Joao Pedro Megalhaes, PhD
10:40 - 11:00
Novel methods for selecting targeted drugs for personalized medicine in oncology

Anton Buzdin, PhD, DSc, President, CEO, Pathway Pharmaceuticals, Hong Kong
11:00 - 11:20
Bioinformatic analysis of the “omics” data from long-lived animals for geroprotector discovery

Joao Pedro De Magalhaes, PhD, Lab Head, University of Liverpool
11:20 - 11:40
In silico screening for novel drugs with geroprotective properties

Alexander Zhavoronkov, PhD, Director, The Biogerontology Research Foundation, CEO, Insilico Medicine, Inc
11:40 - 12:00
Using novel isotopically-fortified organic compounds to slow down the aging processes and treat age related diseases

Robert Molinari, PhD, CEO, Retrotope, Inc
12:00 -13:30
Lunch and Industry symposia
Room 5
Keynote address: R&D productivity: revival or further decline?
13:30 - 14:15
Dr. Joerg Reinhardt, Chairman of the Board of Directors, Novartis


Session II: Drugs with the potential geroprotective properties
Session Chair: Alexey Moskalev, PhD, DSc
14:30-14:40
Introduction to Session II

Bhupinder Bhullar, PhD
14:40 - 15:00
Advances in the Advanced Glycation Endproduct (AGE) breakers

William Bains, PhD, Head of the SENS Laboratory, Cambridge
15:00 - 15:20
Overview of the possible geroprotectors

Sven Bulterijs, PhD, Post-grad researcher, Yale University
15:20 - 15:40
Applied Epigenetics of Aging and Longevity

Olga Kovalchuk, PhD, Professor, Lab Head, University of Lethbridge, Director, Canada Cancer and Aging Research Laboratories
15:40-16:00
Break
16:00 - 17:00
Roundtable Discussion: How can Pharma engage in aging research?

Moderator: Alex Zhavoronkov, PhD


Day 2: Wednesday, September 24, 2014
08:45 - 09:00
Introduction to Forum and Day 2

Forum Chairs: Alex Zhavoronkov, PhD, Bhupinder Bhullar, PhD
Keynotes and Hallmarks of Aging Research
09:00 - 09:20
Rapamycin and other geroprotectors

Mikhail Blagosklonny, MD, PhD, Professor, Editor-in-Chief of Aging, Cell Cylcle and Oncotarget high-impact journals, Rosewell Park, NY
09:20 - 09:40
TBD

Blanka Rogina, PhD, Director Genetics & Developmental Biology Graduate Program, University of Connecticut
09:40 - 10:00
TBD

James Kirkland, MD, PhD, Professor, Mayo Clinic
10:00 - 10:20
How to Solve Genetic Disease on a Population Scale

Barry Merriman, PhD, Professor, UCLA / Lead System Architect, CSO, Thermo Fisher Scientific
10:20 - 10:40
Coffee Break
Session III: Aging Biomarkers: how do we measure aging and geroprotective efficacy
Session Chair: Alexander Bürkle, PhD
10:40 - 11:00
Lessons learned from the EU FP7 MARKAGE Project

Alexander Bürkle, PhD, Professor, EU MARK-AGE Co-ordinator, University of Konstanz
11:00 - 11:20
Comparative genomics of aging and longevity

Vadim Gladyshev, PhD, Professor, Department of Medicine, Harvard Medical School, Director of Redox Medicine, Medicine, Brigham And Women's Hospital, Harvard
11:20 - 11:40
Gene expression patterns in progeria, age-related macular degeneration (AMD) and other age-related diseases

Antonei Benjamin Csoka, PhD, Assoc. Professor, Howard University, CEO, Vision Genomics, Inc
11:40 - 12:00
Genetic and Epigenetic Biomarkers of Aging

Alexey Moskalev, PhD, DSc, Professor, head of the laboratory Moscow Institute of Physics and Technology
12:00 - 13:30
Lunch and Industry Symposia
Room 5
Keynote Address: TBD
13:30 - 14:15
 Dr. Patrick Aebischer,  President Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland
Session IV: Trends in Aging Research for Drug Discovery
Session Chair: Richard Faragher, PhD
14.30 - 15:00
Pharmacological prospects for health span extension

Richard Faragher, Professor, University of Brighton
15:00-15:30
Ageing Research and Regenerative Medicine Industry Outlook

Geoffrey Furlonger, CEO, Aging Analytics, Charles Groome, Head of Communications, Aging Analytics UK
15:30 - 16:00
Big Data in Biomedicine: Applying machine learning to predict the outcomes of biomedical research projects

Dmitry Kaminskiy, Director, Senior Partner, Deep Knowledge Ventures
16:00 - 16:20
Coffee Break
16:20 - 16:40
Industry Partnerships for Ageing Research

David Brindley, Research Fellow , Harvard / University of Oxford
16:40-17:00
Concluding remarks







03.08.14 PROGRAM UPDATE

Note the midday keynotes: 



International Symposium on Geroprotectors: Practical applications of aging research for drug discovery
23.09, Tuesday: Keynotes/General



08.00 - 08.30
Advances in aging biomarkers and drugs with geroprotective properties
Brian Kennedy
Director, CEO
Buck Institute for Aging Research
08.30 - 09.00
New approaches in aging diagnostics and interventions
Charles Cantor
    Professor
Boston University
09.00 - 9.30
TBD
Nir Barzilai
Director
Albert Einstein College of Medicine
9.30-10.30
ROUND TABLE (Bhupinder Bullar to organize): how can large pharma engage in aging research?
Session I: Predicting the activity of geroprotective drugs: in-silico screening, omics data analysis and rational drug design; Session Chair: Joao Pedro Megalhaes, PhD
10.30 - 11.00
Novel methods for selecting targeted drugs for personalized medicine in oncology
Anton Buzdin
President, CEO
Pathway Pharmaceuticals
11.00 - 11.30
Bioinformatic analysis of the “omics” data from long-lived animals for geroprotector discovery
Joao Pedro De Magalhaes
Lab Head
University of Liverpool
11.30 - 12.00
In silico screening for novel drugs with geroprotective properties
Alexander Zhavoronkov
Director
The Biogerontology Research Foundation
Lunch




13.30-14.15
TBD
Dr. Jörg Reinhardt
Chairman
Novartis
Session II: Drugs with the potential geroprotective properties
Session Chair: TBD

14.30 - 15.00
Using novel isotopically-fortified organic compounds to slow down the aging processes
and treat age-related diseases
Robert Molinari
CEO
Retrotope, Inc
15.00 - 15.30
Advances in the Advanced Glycation Endproduct (AGE) breakers
William Bains
Head of the SENS Laboratory
Cambridge
15.30 - 16.00
Overview of the possible geroprotectors
Sven Bulterijs
Post-grad researcher
Yale University
16.00 - 16.30
Coffee Break



16.30 - 17.00
Applied Epigenetics of Aging and Longevity
Olga Kovalchuk
Professor, Lab Head
University of Lethbridge
24.09, Wednesday: Keynotes/General



08.00 - 08.30
Rapamycin and other geroprotectors
Mikhail Blagosklonny
Professor, editor-in-chief of Aging
Rosewell Park, NY
08.30 - 09.00
TBD
Blanka Rogina
Director Genetics & Developmental Biology Graduate Program
University of Connecticut
09.00 - 09.30
TBD
James Kirkland
Professor
Mayo Clinic
09.30 - 10.00
How to Solve Genetic Disease on a Population Scale
Barry Merriman
Professor/ Lead System Architect, CSO
UCLA/Thermo Fisher Scientific
10.00 - 10.30
Coffee Break



Session III: Aging Biomarkers: how do we measure aging and geroprotective efficacy
Session Chair: Alexander Bürkle, PhD
10.30 - 11.00
Lessons learned from the EU FP7 MARKAGE Project
Alexander Bürkle
Professor, MARK-AGE Co-ordinator
University of Konstanz
11.00-11.30
Comparative genomics of aging and longevity
Vadim Gladyshev
Professor, Department of Medicine, Harvard Medical School
Director of Redox Medicine, Brigham And Women's Hospital
Harvard
11.00 - 11.30
Gene expression patterns in progeria and age-related diseases
Antonei Benjamin Csoka
Assoc. Professor
Howard University
11.30 - 12.00
Genetic and Epigenetic Biomarkers of Aging
Alexey A Moskalev
Professor, head of the laboratory
Moscow Institute of Physics and Technology
Lunch




13.30-14.15
TBD
Prof. Patrick Aebischer
President
Ecole
Polytechnique Fédérale de Lausanne (EPFL)
Session IV: Trends in Aging Research for Drug Discovery
Session Chair: Richard Faragher, PhD
14.30 - 15.00
Ageing Research and Regenerative Medicine Industry Outlook
Charles Groome and Geoffrey Furlonger
Head of Communications
Aging Analytics
15.00 - 15.30
Industry Partnerships for Ageing Research
David Brindley
Research Fellow in Cell Therapy Commercialization / Researcher
Harvard Stem Cell Institute / University of Oxford, NDORMS
15.30 - 16.00
Big Data in Biomedicine: Applying machine learning to predict the outcomes of biomedical research projects
Dmitry Kaminskiy
Director, Senior Partner
Deep Knowledge Ventures
16.00 - 16.30
Coffee Break



16.30 - 17.00
TBD
Richard Faragher
Professor
University of
Brighton
Backup keynote speaker (23 or 24)



TBD
New drug discovery: AK-1 for radioprotection, AK-2 for antiviral and AK-3 for anti-aging
Grace Wong
CEO
Actokine
 





Note the midday keynotes: 

Tuesday, September 23     Opening Keynotes   08.30 - 09.00 Brian Kennedy, PhD Director, CEO Buck Institute for Aging Research, USA  Advances in aging biomarkers and drugs with geroprotective properties       09.00 - 09.30 Charles Cantor, PhD Professor Boston University, USA  New approaches in aging diagnostics and interventions       09.30 - 10.00 Nir Barzilai, MD Director Albert Einstein College of Medicine, USA  TBD       10.00 - 10.30 Coffee Break and Networking       Session I: Predicting the activity of geroprotective drugs: in-silico screening, omics data analysis and rational drug design    Session Chair: Joao Pedro Megalhaes, PhD        10.30 - 11.00 Anton Buzdin, PhD, DSc President, CEO Pathway Pharmaceuticals, Limited, Hong Kong  Novel methods for selecting targeted drugs for personalized medicine in oncology       11.00 - 11.30 Joao Pedro Megalhaes, PhD Lab Head University of Liverpool, UK  Bioinformatic analysis of the “omics” data from long-lived animals for geroprotector discovery       11.30 - 12.00 Alex Zhavoronkov, PhD Director The Biogerontology Research Foundation, UK  In silico screening for novel drugs with geroprotective properties       Session II: Drugs with the potential geroprotective properties    Session Chair: Alexey Moskalev, PhD        14.30 - 15.00 Bob Molinari, PhD CEO Retrotope, Inc, USA  "Using novel isotopically-fortified organic compounds to slow down the aging processes and treat age-related diseases"       15.00 - 15.30 William Bains, PhD Head of the SENS Laboratory Cambridge, UK  Advances in the Advanced Glycation Endproduct (AGE) breakers       15.30 - 16.00 Sven Bulterijs Post-grad researcher Yale University, USA  Overview of the possible geroprotectors       16.00 - 16.30 Coffee Break and Networking       16.30 - 17.00 TBD    TBD

Wednesday, September 24     Opening Keynotes   09.00 - 09.30 James Kirkland, MD, PhD Professor Mayo Clinic, USA  TBD       09.30 - 10.00 Barry Merriman, PhD Professor/ Lead System Architect, CSO UCLA/Thermo Fisher Scientific, USA  How to Solve Genetic Disease on a Population Scale       10.00 - 10.30 Coffee Break and Networking       "Session III: Aging Biomarkers: how do we measure aging and geroprotective efficacy?  "    Session Chair: Alexander Bürkle, PhD        10.30 - 11.00 Alexander Bürkle, PhD Professor, MARK-AGE Co-ordinator University of Konstanz, Germany  Lessons learned from the EU FP7 MARK‐AGE Project       11.00 - 11.30 Steven Horvath, PhD Professor of Human Genetics & Biostatistics UCLA, USA  Aging Clock: Epigenetic Biomarkers of Aging       11.30 - 12.00 Alexey Moskalev, PhD, DSc Professor, head of the laboratory Moscow Institute of Physics and Technology, Russia  Genetic and Epigenetic Biomarkers of Aging       "Session IV: Trends in Aging Research and Drug Discovery  "    Session Chair: Richard Faragher, PhD        14.30 - 15.00 Charles Groome Head of Communications Aging Analytics, UK  Ageing Research and Regenerative Medicine Industry Outlook       15.00 - 15.30 David Brindley Research Fellow in Cell Therapy Commercialization / Researcher Harvard Stem Cell Institute / University of Oxford, NDORMS, UK  Industry Partnerships for Ageing Research       15.30 - 16.00 Dmitry Kamenskiy Director, Senior Partner Deep Knowledge Ventures, Hong Kong  Big Data in Biomedicine: Applying machine learning to predict the outcomes of biomedical research projects       16.00 - 16.30 Coffee Break and Networking       16.30 - 17.00 TBD    TBD

0 comments:

Post a Comment

Note: Only a member of this blog may post a comment.